Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 67
Significant growth in GLP-1 market with leading market
share for VictozaⓇ
Global GLP-1 market value and share of total
diabetes care market value
exenatide
leading in all regions
VictozaⓇ sales and GLP-1 value market share
VictozaⓇ GLP-1 value market share
VictozaⓇ
DKK
billion
albiglutide1
70
60
50
exenatide
40
launch
30
20
10-
0
2005
dulaglutide
lixisenatide
GLP-1 share of total
diabetes care market
DKK
billion
FDA/EMA statement on
pancreatic safety³
14%
20
48%
18
12%
16
Dulaglutide
Article on
launch
10%
14
pancreatic safety
12
of incretins²
- 8%
10
VICTOZA
Tiraglutide injection:
- 6%
8
- 4%
6
58%
4
2%
2
49%
41%
75%
68%
0%
0
2009
2013 2014
2017
North Region Region Region Region Region
America Europe AAMEO J&K LATAM China
1 Manufacturing and sale of albiglutide to be discontinued by Jul 2018
2 Butler et al, Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans
With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine
Tumors, Diabetes, Vol. 62, Jul 2013
Egan et al, Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment, The New England
Journal of Medicine 370;9, 27 Feb 2014
Source: IQVIA (formerly IMS) MIDAS, monthly data, Nov 2017 (Note: IQVIA data does not adequately
capture rebates resulting in an overstatement of market value)
FDA: US Food and Drug Administration; EMA: European Medicines Agency
AAMEO: Africa, Asia, Middle-East and Oceania; J&K: Japan & Korea; LATAM: Latin America
Source: Reported sales for FY 2017; IQVIA (formerly IMS) MIDAS, Nov 2017
novo nordiskView entire presentation